PUMA and BIM are required for oncogene inactivation-induced apoptosis

Science Signaling

Volumn 6, Issue 268, 2013, Pages

  Bean, Gregory R ^a,b   Ganesan, Yogesh Tengarai ^a   Dong, Yiyu ^a   Takeda, Shugaku ^a   Liu, Han ^a   Chan, Po M ^a   Huang, Yafen ^a   Chodosh, Lewis A ^c   Zambetti, Gerard P ^d   Hsieh, James J D ^a   Cheng, Emily H Y ^a,e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BIM PROTEIN; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; PUMA PROTEIN; TRANSCRIPTION FACTOR FOXO; ABT-737; APOPTOSIS REGULATORY PROTEIN; BBC3 PROTEIN, HUMAN; BCL 2 LIKE PROTEIN 11; BCL-2-LIKE PROTEIN 11; BIPHENYL DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; LAPATINIB; MEMBRANE PROTEIN; NITROPHENOL; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; SMALL INTERFERING RNA; SULFONAMIDE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; ENZYME ACTIVATION; GENE INACTIVATION; LUNG CANCER; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR REGRESSION; ANIMAL; BREAST TUMOR; CHROMATIN IMMUNOPRECIPITATION; DRUG ANTAGONISM; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETICS; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; FEMALE; FLOW CYTOMETRY; GENE SILENCING; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MICE; NITROPHENOLS; ONCOGENES; PIPERAZINES; PLASMIDS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84875736175     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003483     Document Type: Article

References (55)

1. W. R. Sellers, A blueprint for advancing genetics-based cancer therapy. Cell 147, 26-31 (2011).
2. I. B. Weinstein, Cancer. Addiction to oncogenes - The Achilles heal of cancer. Science 297, 63-64 (2002).
3. R. J. Youle, A. Strasser, The BCL-2 protein family: Opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9, 47-59 (2008).
4. X. Wang, The expanding role of mitochondria in apoptosis. Genes Dev. 15, 2922-2933 (2001).
5. A. Letai, M. C. Bassik, L. D. Walensky, M. D. Sorcinelli, S. Weiler, S. J. Korsmeyer, Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2, 183-192 (2002).
6. M. C. Wei, W. X. Zong, E. H. Cheng, T. Lindsten, V. Panoutsakopoulou, A. J. Ross, K. A. Roth, G. R. MacGregor, C. B. Thompson, S. J. Korsmeyer, Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730 (2001).
7. E. H. Cheng, M. C.Wei, S. Weiler, R. A. Flavell, T.W. Mak, T. Lindsten, S. J. Korsmeyer, BCL-2, BCL-XL sequester BH3 domain-only molecules preventing BAX- and BAKmediated mitochondrial apoptosis. Mol. Cell 8, 705-711 (2001).
8. T. Kuwana, L. Bouchier-Hayes, J. E. Chipuk, C. Bonzon, B. A. Sullivan, D. R. Green, D. D. Newmeyer, BH3 domains of BH3-only proteins differentially regulate Baxmediated mitochondrial membrane permeabilization both directly and indirectly. Mol. Cell 17, 525-535 (2005).
9. M. Certo, V. Del Gaizo Moore, M. Nishino, G. Wei, S. Korsmeyer, S. A. Armstrong, A. Letai, Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9, 351-365 (2006).
10. H. Kim, M. Rafiuddin-Shah, H. C. Tu, J. R. Jeffers, G. P. Zambetti, J. J. Hsieh, E. H. Cheng, Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies. Nat. Cell Biol. 8, 1348-1358 (2006).
11. J. Deng, N. Carlson, K. Takeyama, P. Dal Cin, M. Shipp, A. Letai, BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12, 171-185 (2007).
12. H. Kim, H. C. Tu, D. Ren, O. Takeuchi, J. R. Jeffers, G. P. Zambetti, J. J. Hsieh, E. H. Cheng, Stepwise activation of BAX and BAK by tBID, BIM, and PUMA initiates mitochondrial apoptosis. Mol. Cell 36, 487-499 (2009).
13. S. Desagher, A. Osen-Sand, A. Nichols, R. Eskes, S. Montessuit, S. Lauper, K. Maundrell, B. Antonsson, J. C. Martinou, Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J. Cell Biol. 144, 891-901 (1999).
14. J. F. Lovell, L. P. Billen, S. Bindner, A. Shamas-Din, C. Fradin, B. Leber, D. W. Andrews, Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135, 1074-1084 (2008).
15. E. Gavathiotis, M. Suzuki, M. L. Davis, K. Pitter, G. H. Bird, S. G. Katz, H. C. Tu, H. Kim, E. H. Cheng, N. Tjandra, L. D.Walensky, BAX activation is initiated at a novel interaction site. Nature 455, 1076-1081 (2008).
16. D. Ren, H. C. Tu, H. Kim, G. X. Wang, G. R. Bean, O. Takeuchi, J. R. Jeffers, G. P. Zambetti, J. J. Hsieh, E. H. Cheng, BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 330, 1390-1393 (2010).
17. W. Kolch, A. Pitt, Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 10, 618-629 (2010).
18. Q. B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K. M. Haskell, K. R. Leander, D. DeFeo-Jones, H. E. Huber, N. Rosen, Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 3, e3065 (2008).
19. S. M. Brachmann, I. Hofmann, C. Schnell, C. Fritsch, S. Wee, H. Lane, S. Wang, C. Garcia-Echeverria, S. M. Maira, Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 106, 22299-22304 (2009).
20. A. C. Faber, D. Li, Y. Song, M. C. Liang, B. Y. Yeap, R. T. Bronson, E. Lifshits, Z. Chen, S. M. Maira, C. Garcia-Echeverría, K. K. Wong, J. A. Engelman, Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc. Natl. Acad. Sci. U.S.A. 106, 19503-19508 (2009).
21. E. H. Cheng, C. L. Sawyers, In cancer drug resistance, germline matters too. Nat. Med. 18, 494-496 (2012).
22. Y. Gong, R. Somwar, K. Politi, M. Balak, J. Chmielecki, X. Jiang, W. Pao, Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFRdependent lung adenocarcinomas. PLoS Med. 4, e294 (2007).
23. M. S. Cragg, J. Kuroda, H. Puthalakath, D. C. Huang, A. Strasser, Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 4, 1681-1689 (2007).
24. D. B. Costa, B. Halmos, A. Kumar, S. T. Schumer, M. S. Huberman, T. J. Boggon, D. G. Tenen, S. Kobayashi, BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med. 4, 1669-1679 (2007).
25. J. Deng, T. Shimamura, S. Perera, N. E. Carlson, D. Cai, G. I. Shapiro, K. K. Wong, A. Letai, Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res. 67, 11867-11875 (2007).
26. R. Ley, K. E. Ewings, K. Hadfield, S. J. Cook, Regulatory phosphorylation of Bim: Sorting out the ERK from the JNK. Cell Death Differ. 12, 1008-1014 (2005).
27. E. Dehan, F. Bassermann, D. Guardavaccaro, G. Vasiliver-Shamis, M. Cohen, K. N. Lowes, M. Dustin, D. C. Huang, J. Taunton, M. Pagano, bTrCP- and Rsk1/2- mediated degradation of BimEL inhibits apoptosis. Mol. Cell 33, 109-116 (2009).
28. L. del Peso, M. González-García, C. Page, R. Herrera, G. Nuñez, Interleukin-3- induced phosphorylation of BAD through the protein kinase Akt. Science 278, 687-689 (1997).
29. S. R. Datta, H. Dudek, X. Tao, S. Masters, H. Fu, Y. Gotoh, M. E. Greenberg, Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241 (1997).
30. S. E. Moody, C. J. Sarkisian, K. T. Hahn, E. J. Gunther, S. Pickup, K. D. Dugan, N. Innocent, R. D. Cardiff, M. D. Schnall, L. A. Chodosh, Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451-461 (2002).
31. K. Politi, M. F. Zakowski, P. D. Fan, E. A. Schonfeld, W. Pao, H. E. Varmus, Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev. 20, 1496-1510 (2006).
32. C. Clybouw, D. Merino, T. Nebl, F. Masson, M. Robati, L. O'Reilly, A. Hubner, R. J. Davis, A. Strasser, P. Bouillet, Alternative splicing of Bim and Erk-mediated BimEL phosphorylation are dispensable for hematopoietic homeostasis in vivo. Cell Death Differ. 19, 1060-1068 (2012).
33. H. You, M. Pellegrini, K. Tsuchihara, K. Yamamoto, G. Hacker, M. Erlacher, A. Villunger, T. W. Mak, FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J. Exp. Med. 203, 1657-1663 (2006).
34. Y. Zhao, J. L. Coloff, E. C. Ferguson, S. R. Jacobs, K. Cui, J. C. Rathmell, Glucose metabolism attenuates p53 and Puma-dependent cell death upon growth factor deprivation. J. Biol. Chem. 283, 36344-36353 (2008).
35. E. L. Greer, A. Brunet, FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410-7425 (2005).
36. B. Gan, C. Lim, G. Chu, S. Hua, Z. Ding, M. Collins, J. Hu, S. Jiang, E. Fletcher-Sananikone, L. Zhuang, M. Chang, H. Zheng, Y. A. Wang, D. J. Kwiatkowski, W. G. Kaelin Jr., S. Signoretti, R. A. DePinho, FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18, 472-484 (2010).
37. P. F. Dijkers, R. H. Medema, J. W. Lammers, L. Koenderman, P. J. Coffer, Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr. Biol. 10, 1201-1204 (2000).
38. J. Gilley, P. J. Coffer, J. Ham, FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J. Cell Biol. 162, 613-622 (2003).
39. M. Stahl, P. F. Dijkers, G. J. Kops, S. M. Lens, P. J. Coffer, B. M. Burgering, R. H. Medema, The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 168, 5024-5031 (2002).
40. A. C. Faber, R. B. Corcoran, H. Ebi, L. V. Sequist, B. A. Waltman, E. Chung, J. Incio, S. R. Digumarthy, S. F. Pollack, Y. Song, A. Muzikansky, E. Lifshits, S. Roberge, E. J. Coffman, C. H. Benes, H. L. Gómez, J. Baselga, C. L. Arteaga, M. N. Rivera, D. Dias-Santagata, R. K. Jain, J. A. Engelman, BIM expression in treatment-naïve cancers predicts responsiveness to kinase inhibitors. Cancer Discov. 1, 352-365 (2011).
41. W. Pao, V. A. Miller, K. A. Politi, G. J. Riely, R. Somwar, M. F. Zakowski, M. G. Kris, H. Varmus, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2, e73 (2005).
42. V. Del Gaizo Moore, J. R. Brown, M. Certo, T. M. Love, C. D. Novina, A. Letai, Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest. 117, 112-121 (2007).
43. S. P. Garrison, D. C. Phillips, J. R. Jeffers, J. E. Chipuk, M. J. Parsons, J. E. Rehg, J. T. Opferman, D. R. Green, G. P. Zambetti, Genetically defining the mechanism of Puma- and Bim-induced apoptosis. Cell Death Differ. 19, 642-649 (2012).
44. J. A. Engelman, L. Chen, X. Tan, K. Crosby, A. R. Guimaraes, R. Upadhyay, M. Maira, K. McNamara, S. A. Perera, Y. Song, L. R. Chirieac, R. Kaur, A. Lightbown, J. Simendinger, T. Li, R. F. Padera, C. García- Echeverría, R. Weissleder, U. Mahmood, L. C. Cantley, K. K. Wong, Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat. Med. 14, 1351-1356 (2008).
45. M. L. Sos, S. Fischer, R. Ullrich, M. Peifer, J. M. Heuckmann, M. Koker, S. Heynck, I. Stückrath, J. Weiss, F. Fischer, K. Michel, A. Goel, L. Regales, K. A. Politi, S. Perera, M. Getlik, L. C. Heukamp, S. Ansén, T. Zander, R. Beroukhim, H. Kashkar, K. M. Shokat, W. R. Sellers, D. Rauh, C. Orr, K. P. Hoeflich, L. Friedman, K. K. Wong, W. Pao, R. K. Thomas, Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. U.S.A. 106, 18351-18356 (2009).
46. K. E. O'Reilly, F. Rojo, Q. B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, J. Baselga, N. Rosen, mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
47. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, V. Serra, P. K. Majumder, J. Baselga, N. Rosen, AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 19, 58-71 (2011).
48. A. Carracedo, L. Ma, J. Teruya-Feldstein, F. Rojo, L. Salmena, A. Alimonti, A. Egia, A. T. Sasaki, G. Thomas, S. C. Kozma, A. Papa, C. Nardella, L. C. Cantley, J. Baselga, P. P. Pandolfi, Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
49. K. Okamoto, I. Okamoto, W. Okamoto, K. Tanaka, K. Takezawa, K. Kuwata, H. Yamaguchi, K. Nishio, K. Nakagawa, Role of survivin in EGFR inhibitor- induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 70, 10402-10410 (2010).
50. J. Tanizaki, I. Okamoto, S. Fumita, W. Okamoto, K. Nishio, K. Nakagawa, Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene 30, 4097-4106 (2011).
51. T. N. Chonghaile, A. Letai, Mimicking the BH3 domain to kill cancer cells. Oncogene 27 (suppl. 1), S149-S157 (2008).
52. H. C. Tu, D. Ren, G. X. Wang, D. Y. Chen, T. D. Westergard, H. Kim, S. Sasagawa, J. J. Hsieh, E. H. Cheng, The p53-cathepsin axis cooperates with ROS to activate programmed necrotic death upon DNA damage. Proc. Natl. Acad. Sci. U.S.A. 106, 1093-1098 (2009).
53. H. Liu, S. Takeda, R. Kumar, T. D. Westergard, E. J. Brown, T. K. Pandita, E. H. Cheng, J. J. Hsieh, Phosphorylation of MLL by ATR is required for execution of mammalian S-phase checkpoint. Nature 467, 343-346 (2010).
54. J. R. Jeffers, E. Parganas, Y. Lee, C. Yang, J. Wang, J. Brennan, K. H. MacLean, J. Han, T. Chittenden, J. N. Ihle, P. J. McKinnon, J. L. Cleveland, G. P. Zambetti, Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 4, 321-328 (2003).
55. O. Takeuchi, J. Fisher, H. Suh, H. Harada, B. A. Malynn, S. J. Korsmeyer, Essential role of BAX,BAK in B cell homeostasis and prevention of autoimmune disease. Proc. Natl. Acad. Sci. U.S.A. 102, 11272-11277 (2005).